Beam Therapeutics BEAM 深 沪
等待开盘 06-30 09:30:00 美东时间
34.95
+0.140
+0.40%
华盛通- 最 高36.75
- 今 开35.006
- 成交量 289.43万股
- 最 低 34.50
- 昨 收 34.81
- 总市值 35.96亿
- 52周最高 36.88
- 市盈率 静 --
- 换手率 2.81%
- 52周最低 15.60
- 委 比 -58.86%
- 总股本 1.03亿
- 历史最高 138.522
- 量 比 0.89
- 振 幅 6.46%
- 历史最低 13.00
- 每 手 1
- 风险率 4.62%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze
Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names where bearish positioning has reached extreme territory, setting the stage for violent moves if sentiment flips. LCID stock is moving. See the chart and price action here. For short sellers, these are h...
06-29 22:35
美股夜盘 | Horizon Quantum Holdings Ltd Class A涨7.53%，Beam Therapeutics涨6.11%
Horizon Quantum Holdings Ltd Class A涨7.53%；Beam Therapeutics涨6.11%；Infleqtion, Inc.涨4.43%
06-23 15:01
美股夜盘 | Horizon Quantum Holdings Ltd Class A涨10.60%，Beam Therapeutics涨8.13%
Horizon Quantum Holdings Ltd Class A涨10.60%；Beam Therapeutics涨8.13%；Infleqtion, Inc.涨7.39%
06-23 13:01
The FDA Clears Beam Therapeutics' Investigational New Drug Application For BEAM-304 For Phenylketonuria
Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for BEAM-304 for the treatment of phe...
06-18 19:09
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration
Beam Therapeutics' BEAM-304, a base-editing therapy for phenylketonuria (PKU), has received FDA IND clearance. The therapy aims to correct single-base mutations in the PAH gene to reduce toxic phenylalanine levels and enable dietary normalization. Designed as a scalable platform, BEAM-304 could address multiple PKU-causing mutations within a single clinical program. Preclinical data show promise, with normalized Phe levels in mouse models. Beam p...
06-18 11:00
Cathie Wood Sells $12.7 Million Worth Of Archer Aviation Stock, Ark Invest Picks Up DoorDash And Pony AI Amid Robotaxi Push
On Monday, June 8, 2026, Ark Invest sold $12.7M in Archer Aviation shares while adding positions in DoorDash and Pony AI's robotaxi play.
06-09 10:48
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
Bernstein Maintains Outperform on Beam Therapeutics, Lowers Price Target to $39
Bernstein analyst William Pickering maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and lowers the price target from $40 to $39.
05-14 02:34
财报速睇 | Beam Therapeutics 2026财年Q1营收0.32亿美元，同比增长357.1%；归母净利润亏损0.94亿美元，同比亏损缩窄13.0%
华盛资讯5月7日讯，Beam Therapeutics公布2026财年Q1业绩，公司Q1营收0.32亿美元，同比增长357.1%，归母净利润亏损0.94亿美元，同比亏损缩窄13.0%。
05-07 20:30
